AGM Information • Jun 28, 2013
AGM Information
Open in ViewerOpens in native device viewer
News Details
Corporate | 28 June 2013 19:00
Cytos Biotechnology Ltd, Annual Shareholders’ Meeting: Shareholders approved all proposals and resolutions. (with additional features)
Cytos Biotechnology AG / Key word(s): AGM/EGM
28.06.2013 / 19:00
Annual Shareholders’ Meeting of Cytos Biotechnology Ltd: Shareholders approve all resolutions
Schlieren (Zurich), Switzerland, 28 June 2013 – Cytos Biotechnology Ltd (SIX:CYTN) today announced that its shareholders have approved all resolutions at the Annual Shareholders’ Meeting 2013.
The Annual Shareholders’ Meeting of Cytos Biotechnology Ltd took place at the company’s headquarters in Schlieren (Zurich), Switzerland. It was attended by 38 shareholders. 12,584,907 shares or 56.15% of a total of 22,411,431 shares were represented.
For further information, please contact:
Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
e-mail: [email protected]
About Cytos Biotechnology Ltd
Cytos is a public biopharmaceutical company focused on the development of targeted immuno-therapies. The Company’s lead product candidate CYT003 is a first-in-class immune modulator in Phase 2 clinical development as a potential new treatment for allergic asthma.
CYT003 acts via a novel, allergen-independent mechanism of action to selectively suppress the body’s immune response to allergens, a predominant risk factor for asthma. In a successfully completed Phase 2a study, CYT003 was shown to maintain asthma control and lung function in patients with persistent allergic asthma, even as standard inhaled corticosteroid treatment was withdrawn. CYT003 has been shown to be safe in over 450 patients to date.
Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich. It is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.
This foregoing press release may contain forward-looking statements that include words or phrases such as ‘are intended for’, ‘are designed to’, or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any further therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The Company assumes no responsibility to update forward-looking statements or adapt them to future events or developments.
End of Corporate News
+++++
Additional features:
Document: http://n.equitystory.com/c/fncls.ssp?u=XJRVBCXSFS
Document title: AGM
28.06.2013 This press release was distributed by EQS CORPORATE COMMUNICATIONS.
www.eqs.com – news archive: www.eqs.com/ch/presskit
The issuer is responsible for the contents of the release.
| Language: | English |
| Company: | Cytos Biotechnology AG |
| Wagistr. 25 | |
| 8952 Schlieren | |
| Switzerland | |
| Phone: | +41 44 733 4747 |
| Fax: | +41 44 733 4740 |
| E-mail: | [email protected] |
| Internet: | www.cytos.com |
| ISIN: | CH0011025217, CH0029060735 |
| Valor: | – |
| Listed: | Freiverkehr in Berlin, München, Stuttgart; Frankfurt in Open Market ; SIX |
| End of News | EQS Group AG News-Service |
| - - - |
| 218808 28.06.2013 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.